Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

LYMPHIR commercial availability planned for the fourth quarter of 2025

$12.5 million in gross financings raised during the quarter by Citius Pharmaceuticals, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive successful market introduction

Read more at prnewswire.com